BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 24700751)

  • 1. Monitoring hypoxia and vasculature during bevacizumab treatment in a murine colorectal cancer model.
    Heijmen L; Ter Voert EG; Punt CJ; Heerschap A; Oyen WJ; Bussink J; Sweep CG; Laverman P; Span PN; de Geus-Oei LF; Boerman OC; van Laarhoven HW
    Contrast Media Mol Imaging; 2014; 9(3):237-45. PubMed ID: 24700751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring the effects of bevacizumab beyond progression in a murine colorectal cancer model: a functional imaging approach.
    Heijmen L; Punt CJ; Ter Voert EG; de Geus-Oei LF; Heerschap A; Bussink J; Sweep CG; Zerbi V; Oyen WJ; Span PN; Boerman O; van Laarhoven HW
    Invest New Drugs; 2013 Aug; 31(4):881-90. PubMed ID: 23325291
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Grkovski M; Emmas SA; Carlin SD
    J Nucl Med; 2017 Oct; 58(10):1567-1573. PubMed ID: 28360207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imaging hypoxia after oxygenation-modification: comparing [18F]FMISO autoradiography with pimonidazole immunohistochemistry in human xenograft tumors.
    Troost EG; Laverman P; Kaanders JH; Philippens M; Lok J; Oyen WJ; van der Kogel AJ; Boerman OC; Bussink J
    Radiother Oncol; 2006 Aug; 80(2):157-64. PubMed ID: 16905213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. (99)mTc-(CO)(3) His-annexin A5 micro-SPECT demonstrates increased cell death by irinotecan during the vascular normalization window caused by bevacizumab.
    Vangestel C; Van de Wiele C; Van Damme N; Staelens S; Pauwels P; Reutelingsperger CP; Peeters M
    J Nucl Med; 2011 Nov; 52(11):1786-94. PubMed ID: 22045708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models.
    O'Donoghue JA; Zanzonico P; Pugachev A; Wen B; Smith-Jones P; Cai S; Burnazi E; Finn RD; Burgman P; Ruan S; Lewis JS; Welch MJ; Ling CC; Humm JL
    Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1493-502. PubMed ID: 15817355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PET of hypoxia with 89Zr-labeled cG250-F(ab')2 in head and neck tumors.
    Hoeben BA; Kaanders JH; Franssen GM; Troost EG; Rijken PF; Oosterwijk E; van Dongen GA; Oyen WJ; Boerman OC; Bussink J
    J Nucl Med; 2010 Jul; 51(7):1076-83. PubMed ID: 20554724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bevacizumab-induced normalization of blood vessels in tumors hampers antibody uptake.
    Arjaans M; Oude Munnink TH; Oosting SF; Terwisscha van Scheltinga AG; Gietema JA; Garbacik ET; Timmer-Bosscha H; Lub-de Hooge MN; Schröder CP; de Vries EG
    Cancer Res; 2013 Jun; 73(11):3347-55. PubMed ID: 23580572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiangiogenic therapy for primary liver cancer: correlation of changes in dynamic contrast-enhanced magnetic resonance imaging with tissue hypoxia markers and clinical response.
    Yopp AC; Schwartz LH; Kemeny N; Gultekin DH; Gönen M; Bamboat Z; Shia J; Haviland D; D'Angelica MI; Fong Y; DeMatteo RP; Allen PJ; Jarnagin WR
    Ann Surg Oncol; 2011 Aug; 18(8):2192-9. PubMed ID: 21286939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in non-small cell lung cancer assessed by 18F-Fluoromisonidazole and 18F-FDG PET.
    Cherk MH; Foo SS; Poon AM; Knight SR; Murone C; Papenfuss AT; Sachinidis JI; Saunder TH; O'Keefe GJ; Scott AM
    J Nucl Med; 2006 Dec; 47(12):1921-6. PubMed ID: 17138734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DCE-MRI and Quantitative Histology Reveal Enhanced Vessel Maturation but Impaired Perfusion and Increased Hypoxia in Bevacizumab-Treated Cervical Carcinoma.
    Hauge A; Gaustad JV; Huang R; Simonsen TG; Wegner CS; Andersen LMK; Rofstad EK
    Int J Radiat Oncol Biol Phys; 2019 Jul; 104(3):666-676. PubMed ID: 30858145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring therapeutic efficacy of sunitinib using [(18)F]FDG and [(18)F]FMISO PET in an immunocompetent model of luminal B (HER2-positive)-type mammary carcinoma.
    Thézé B; Bernards N; Beynel A; Bouet S; Kuhnast B; Buvat I; Tavitian B; Boisgard R
    BMC Cancer; 2015 Jul; 15():534. PubMed ID: 26198000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of hypoxia in an experimental rat tumour model by [(18)F]fluoromisonidazole PET and immunohistochemistry.
    Dubois L; Landuyt W; Haustermans K; Dupont P; Bormans G; Vermaelen P; Flamen P; Verbeken E; Mortelmans L
    Br J Cancer; 2004 Nov; 91(11):1947-54. PubMed ID: 15520822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-VEGF antibody therapy induces tumor hypoxia and stanniocalcin 2 expression and potentiates growth of human colon cancer xenografts.
    Miyazaki S; Kikuchi H; Iino I; Uehara T; Setoguchi T; Fujita T; Hiramatsu Y; Ohta M; Kamiya K; Kitagawa K; Kitagawa M; Baba S; Konno H
    Int J Cancer; 2014 Jul; 135(2):295-307. PubMed ID: 24375080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamic (18)F-FDG-PET for monitoring treatment effect following anti-angiogenic therapy in triple-negative breast cancer xenografts.
    Kristian A; Revheim ME; Qu H; Mælandsmo GM; Engebråten O; Seierstad T; Malinen E
    Acta Oncol; 2013 Oct; 52(7):1566-72. PubMed ID: 23984812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bevacizumab Induces Acute Hypoxia and Cancer Progression in Patients with Refractory Breast Cancer: Multimodal Functional Imaging and Multiplex Cytokine Analysis.
    Ueda S; Saeki T; Osaki A; Yamane T; Kuji I
    Clin Cancer Res; 2017 Oct; 23(19):5769-5778. PubMed ID: 28679773
    [No Abstract]   [Full Text] [Related]  

  • 17. Complementary information from magnetic resonance imaging and (18)F-fluoromisonidazole positron emission tomography in the assessment of the response to an antiangiogenic treatment in a rat brain tumor model.
    Valable S; Petit E; Roussel S; Marteau L; Toutain J; Divoux D; Sobrio F; Delamare J; Barré L; Bernaudin M
    Nucl Med Biol; 2011 Aug; 38(6):781-93. PubMed ID: 21843775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PET imaging of tumor hypoxia using 18F-labeled pimonidazole.
    Busk M; Jakobsen S; Horsman MR; Mortensen LS; Iversen AB; Overgaard J; Nordsmark M; Ji X; Lee DY; Raleigh JR
    Acta Oncol; 2013 Oct; 52(7):1300-7. PubMed ID: 23962243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in gliomas using 18F-fluoromisonidazole, 18F-FDG PET, and immunohistochemical studies.
    Cher LM; Murone C; Lawrentschuk N; Ramdave S; Papenfuss A; Hannah A; O'Keefe GJ; Sachinidis JI; Berlangieri SU; Fabinyi G; Scott AM
    J Nucl Med; 2006 Mar; 47(3):410-8. PubMed ID: 16513609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vascular and metabolic response to bevacizumab-containing regimens in two patients with colorectal liver metastases measured by dynamic contrast-enhanced MRI and dynamic 18F-FDG-PET.
    Vriens D; de Geus-Oei LF; Heerschap A; van Laarhoven HW; Oyen WJ
    Clin Colorectal Cancer; 2011 Mar; 10(1):E1-5. PubMed ID: 21609927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.